# Evandro de Azambuja

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/evandro-de-azambuja/

## Facts

| Field | Value |
| --- | --- |
| Citations | 39,442 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 86 |
| i10-index | 287 |
| Last Known Institution | Université Libre de Bruxelles |
| OpenAlex ID | https://openalex.org/A5081663693 |
| ORCID iD | https://orcid.org/0000-0001-9501-4509 |
| Works | 725 |

## Researcher papers

- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the-2/)
- [Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer](https://scholariq.org/papers/adjuvant-olaparib-for-patients-with-i-brca1-i-or-i-brca2-i-mutated-breast-cancer/)
- [ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer](https://scholariq.org/papers/esmo-clinical-practice-guideline-for-the-diagnosis-staging-and-treatment-of/)
- [Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations](https://scholariq.org/papers/management-of-cardiac-disease-in-cancer-patients-throughout-oncological/)
- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [HER2-Low Breast Cancer: Molecular Characteristics and Prognosis](https://scholariq.org/papers/her2-low-breast-cancer-molecular-characteristics-and-prognosis/)
- [Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials](https://scholariq.org/papers/anthracycline-containing-and-taxane-containing-chemotherapy-for-early-stage/)
- [Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative](https://scholariq.org/papers/genomic-and-transcriptomic-analyses-of-breast-cancer-primaries-and-matched/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

## Researcher university

- [Université Libre de Bruxelles](https://scholariq.org/institutions/universite-libre-de-bruxelles/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.